Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
November 19, 2007
- Daiichi Sankyo to File Applications for Prasugrel in US, Europe
November 19, 2007
- Operating Profits Up for All 9 Leading Domestic Companies
November 19, 2007
- Takeda: Overseas Sales Exceed 50% Driven by Actos
November 19, 2007
- Astellas: Overseas Sales Exceed 50% of Total Sales
November 19, 2007
- DSP: 4 Strategic Products Show Strong Sales
November 19, 2007
- Taisho: Stock Levels Normalized
November 19, 2007
- PMDA to Introduce Project Management System to Expedite NDA Review Process
November 19, 2007
- MTPC to Create Subsidiary to Promote Generic Drugs Business
November 19, 2007
- REGULATORY NEWS IN BRIEF
November 19, 2007
- Shionogi: Crestor Increases Profits with Royalty Income
November 19, 2007
- Prasugrel Reduces Risk of Serious CV Events by 19%: AHA
November 19, 2007
- Global Pharma Market to Grow 5-6% in 2008: IMS Health
November 19, 2007
- R&D NEWS IN BRIEF
November 19, 2007
- BUSINESS NEWS IN BRIEF
November 19, 2007
- Generics Dispensed for 1.4% of Prescriptions Permitting Substitution: Korosho Survey
November 19, 2007
- NEW PRODUCTS
November 19, 2007
- GENERICS NEWS IN BRIEF
November 19, 2007
- Council to Recommend Reductions in Medical Fees, NHI Drug Prices
November 19, 2007
- Korosho to Determine Information Needed When Selling OTC Drugs
November 19, 2007
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…